Axis Direct picks JSW Steel, Balrampur Chini, Biocon and 2 other stocks for 15 days; check out targets and stop losses

Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.

ZeeBiz WebTeam | Sep 16, 2024, 06:20 PM IST

Sensex jumped 97.84 points to settle at an all-time closing high of 82,988.78 today (September 16) while Nifty was 27.25 points up at 25,383.75.

Images: Pixabay, Pexels, Freepik

1/6

Axis Direct picks 5 stocks for 15 days

Axis Direct picks 5 stocks for 15 days

Brokerage Axis Direct has chosen five stocks for positional traders. These stocks include Vinati Organics, JSW Steel, Balrampur Chini, Biocon, and Strides Pharma. Let's take a look at their target prices.

 

2/6

Vinati Organics share price target

Vinati Organics share price target

Axis Direct has given a 'buy' rating on Vinati Organics. The brokerage has given a target of Rs 2,089 and a stop loss of Rs 1,913. This means the stock has an upside of seven per cent from its last closing price.

3/6

Share price target JSW Steel

Share price target JSW Steel

Axis Direct has given a 'buy' rating on JSW Steel. The brokerage has given a target of Rs 1,026 and a stop loss of Rs 950. This means the stock has an upside of six per cent from its last closing price.

4/6

Balrampur Chini share price target

Balrampur Chini share price target

Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.

5/6

Share price target Biocon

Share price target Biocon

Axis Direct has given a 'buy' rating on Biocon. The brokerage has given a target of Rs 409.20 and a stop loss of Rs 382. This means the stock has an upside of five per cent from its last closing price.

6/6

Strides Pharma share price target

Strides Pharma share price target

Axis Direct has given a 'buy' rating on Strides Pharma. The brokerage has given a target of Rs 1,550 and a stop loss of Rs 1,369. This means the stock has an upside of 11 per cent from its last closing price.

The views/suggestions/advice expressed here in this article are solely by the brokerage firm. Zee Business suggests its readers consult their investment advisers before making any financial decision.

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x